SHR-1501 demonstrated potent antitumor activity, especially when combined with PD-1 mAb. Its mechanism likely involves promoting CD8+ T cell and NK cell infiltration and enhancing M1 macrophage activity. These findings provide evidence for further clinical trials exploring SHR-1501 in nonsmall cell lung cancer (NSCLC) therapy.

4 months ago

Journal

KRAS (KRAS proto-oncogene GTPase) • CD8 (cluster of differentiation 8)

KRAS G12D • KRAS G12

SHR-1501

5ms

Phase I/II Clinical Study of SHR-1501 Combined With Adbelizumab in Patients With Malignant Tumors (clinicaltrials.gov)

P1/2, N=203, Not yet recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd.

5 months ago

New P1/2 trial

AiRuiLi (adebrelimab) • SHR-1501

1year

SHR-1501 Combined With SHR-2005 for High-Risk Non-Muscle Invasive Bladder Cancer Which is Not Completely Resectable by TURBt (clinicaltrials.gov)

P1/2, N=58, Not yet recruiting, Fudan University

1 year ago

New P1/2 trial

SHR-1501

almost3years

A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors (clinicaltrials.gov)

P1, N=14, Active, not recruiting, Jiangsu HengRui Medicine Co., Ltd. | Trial completion date: Dec 2022 --> Mar 2023 | Trial primary completion date: Sep 2022 --> Mar 2023

almost 3 years ago

Trial completion date • Trial primary completion date • Combination therapy • Metastases

CD8 (cluster of differentiation 8)

AiRuiLi (adebrelimab) • SHR-1501

over3years

A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors (clinicaltrials.gov)

P1, N=14, Active, not recruiting, Jiangsu HengRui Medicine Co., Ltd. | Recruiting --> Active, not recruiting | N=104 --> 14 | Trial completion date: Jun 2023 --> Dec 2022 | Trial primary completion date: Jun 2022 --> Sep 2022

over 3 years ago

Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy

CD8 (cluster of differentiation 8)

AiRuiLi (adebrelimab) • SHR-1501